Travere Therapeutics (TVTX) Change in Cash (2012 - 2026)

Travere Therapeutics has reported Change in Cash for 15 years, with the latest figure at -$14.7 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 536.44% year-over-year to -$14.7 million; the trailing twelve-month figure through Mar 2026 stood at $16.5 million (down 11.7% YoY), and the FY2025 full-year result was $34.5 million, up 9510.03% from the prior year.
• Change in Cash for Q1 2026 stood at -$14.7 million, up from -$17.9 million in the prior quarter.
• The five-year high for Change in Cash was $99.7 million in Q1 2023, with the low at -$90.5 million in Q2 2023.
• Historically, Change in Cash has averaged -$5.1 million across 5 years, with a median of -$11.0 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Cash tumbled 681.16% — and 2025, when it surged 768.77%.
• Travere Therapeutics' Change in Cash stood at -$89.6 million in 2022, then grew by 3.99% to -$86.1 million in 2023, then soared by 125.71% to $22.1 million in 2024, then slumped by 180.88% to -$17.9 million in 2025, then increased by 18.01% to -$14.7 million in 2026.
• The last three Change in Cash figures came in at -$14.7 million (Q1 2026), -$17.9 million (Q4 2025), and $35.8 million (Q3 2025), per Business Quant data.